Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that binds to low-density lipoprotein receptors (LDL receptors), which stops LDL being removed from the blood, leading to an increase in blood levels of LDL. The PCSK9 inhibitor blocks the PCSK9 enzyme, resulting in more LDL receptors available to remove LDL from the blood, which produces in a decrease in LDL blood levels.
Data
Source:drugs.com
Praluent
PRALUENT is a medication used to lower cholesterol levels in the blood. It belongs to a class of drugs called PCSK9 inhibitors, which work by blocking a protein that reduces the liver's ability to remove LDL cholesterol from the blood. By inhibiting this protein, PRALUENT helps to lower LDL cholesterol levels and reduce the risk of cardiovascular events such as heart attacks and strokes. It is typically prescribed to individuals with high cholesterol who have not responded well to other cholesterol-lowering medications or who have a genetic condition that causes high cholesterol. PRALUENT is administered as a subcutaneous injection and is usually used in combination with a healthy diet and exercise.
REPATHA is a medication used to lower cholesterol levels in the blood. It belongs to a class of drugs called PCSK9 inhibitors, which work by blocking a protein that reduces the liver's ability to remove LDL cholesterol from the blood. By inhibiting this protein, REPATHA helps to lower LDL cholesterol levels and reduce the risk of cardiovascular events such as heart attacks and strokes. It is typically prescribed to patients with high cholesterol who have not responded well to other cholesterol-lowering medications or who have a genetic condition that causes high cholesterol. REPATHA is administered as a subcutaneous injection and is usually taken once every two weeks or once every four weeks, depending on the dosage prescribed by the healthcare provider.
